Arrow® PICC with Chlorag+ard®
Technology Shows Greatest Reduction of Thrombus Formation when
Compared to Non-Eluting Antithrombogenic Technologies
WAYNE, Pa.--(BUSINESS WIRE)--Jan. 11, 2016--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, announces the results of a
pre-clinical intravascular study, highlighting Arrow® PICC
with Chlorag+ard® Technology and its ability to
significantly reduce thrombus formation when compared to competitive
non-eluting antithrombogenic technologies.
The pre-clinical study titled “Catheter Technologies: Is eluting
technology or non-eluting technology more effective in preventing
thrombus accumulation?” by Kamna Giare-Patel, MS, et al, evaluated
the effectiveness of three types of peripherally inserted central venous
catheters (PICCs) with antithrombogenic properties as compared to
uncoated PICCs in a clinically simulated ovine model. The three test
groups consisted of PICCs with fluorine-based technology (AngioDynamics®
BioFlo™ PICC with Endexo™ Technology),
chlorhexidine-based technology (Arrow® PICC with Chlorag+ard®
Technology) and Amphiphilic PMEA based technology (Terumo®
Xcoating™).
After 30 days, all catheters were explanted by dissecting the vessels
open. The amount of accumulated thrombus on the catheter surfaces was
measured for thrombus weight and length. Arrow® PICC with
Chlorag+ard® Technology showed the least amount of
thrombus as a result of greatest weight reduction (81%) and length
reduction (76%) when compared to the uncoated control catheter. Overall
results are in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
FLUORINE-
|
|
CHLORHEXIDINE-
|
|
|
|
|
|
PICC GROUP
|
|
BASED
|
|
BASED
|
|
PMEA-BASED
|
|
UNCOATED
|
|
|
|
(GROUP A)
|
|
(GROUP B)
|
|
(GROUP C)
|
|
(GROUP D)
|
|
Technology Type
|
|
Non-eluting
|
|
Eluting
|
|
Non-eluting
|
|
N/A
|
|
Avg. Weight (g)
|
|
0.161
|
|
0.066
|
|
0.208
|
|
0.353
|
|
Avg. Length (cm)
|
|
4.2
|
|
1.7
|
|
3.0
|
|
7.0
|
|
% Weight Reduction
|
|
|
|
|
|
|
|
|
|
(compared to control)
|
|
54%
|
|
81%
|
|
41%
|
|
N/A
|
|
% Length Reduction
|
|
|
|
|
|
|
|
|
|
(compared to control)
|
|
40%
|
|
76%
|
|
57%
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
The authors of the poster concluded that the eluting technology (Arrow®
PICC with Chlorag+ard® Technology), compared to
the two (2) non-eluting technologies, showed the best outcomes by
exhibiting the most effective prevention of thrombus accumulation after
a 30-day dwell time. The study was funded by, and authors are employed
by, Teleflex Incorporated.
Chlorag+ard® Technology treatment on the external
surface of the catheter body as well as the entire fluid pathway of the
catheter has been shown to be effective in reducing microbial
colonization and thrombus accumulation on catheter surfaces. The Arrow®
PICC with Chlorag+ard® Technology offers
protection that is designed to reduce the risk of catheter-related
occlusion, thrombus accumulation, intimal hyperplasia and catheter
colonization for at least thirty (30) days. Additional information may
be found at chloragard.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
AngioDynamics, BioFlo and Endexo are trademarks or registered
trademarks of AngioDynamics, Inc.
Terumo and Xcoating are trademarks or registered trademarks of Terumo
Medical Corporation.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rusch, Weck and Chlorag+ard are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2016 Teleflex Incorporated. All rights reserved. MC-001893
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005005/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836